Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tech Transfer Roundup: UCSD Sees Many Benefits From Entrepreneurs In Residence Program

Executive Summary

Asterias obtains IP estate related to ischemic stroke from University of California. Plus Apeiron, Qualigen, Biovaxys and AbbVie turn to academic partners for early-stage cancer assets.

You may also be interested in...



Herantis Awaits CDNF Results This Year In Parkinson's Disease

Executive Interview: Reducing “ER stress” is one of the potential mechanisms of action of a novel candidate Parkinson’s agent being evaluated by Finland’s Herantis, which completed an additional stock market listing, in Sweden, last month.

Tech Transfer Roundup: Trio Of Deals Bolster Spherix’s Cancer Strategy

The New York biotech announces option deals with two universities, asset license from CBM BioPharma. Bayer inks research collaborations with Japan’s RiKen and with a pair of Boston research hospitals.

Korean Industry Demands Bold Support Amid US Policy Moves

As the global biopharma industry attempts to understand the implications of the US Inflation Reduction Act, South Korea's biopharma industry is pressing its government to come up with "bold and rapid" additional measures to reduce the possible negative impact of the legislation and other US policies with international implications, and to support the sector amid generally rising global competition.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC123464

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel